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ABSTRACT 
INTRODUCTION: The course and prognosis of cardiac sar-
coidosis (CS) are sparsely described. The purpose of this 
study was to assess the clinical presentation, treatment re-
sponse and prognosis for patients with CS. 
METHODS: This was a single-centre retrospective study of 
patients with CS from 2006 to 2016. A total of 197 patients 
with a sarcoidosis diagnosis were screened, and 17 patients 
(mean age 46.9 years, 59% men) were diagnosed with CS 
based on Japanese Ministry of Health and Welfare criteria; 
53% were diagnosed by a positive MRI, 29% by endomyo-
cardial biopsy. Of 17 patients, nine (53%) had a left ventri-
cular ejection fraction (LVEF) < 45% at the time of diagnosis. 
The median follow-up was four years. In 13 patients, an im-
plantable defibrillator was used and six of these (46%) re-
ceived first appropriate shock therapy after a mean follow-
up of two years. A total of 11 (65%) patients were treated 
with prednisolone and five (45%) of these 11 patients were 
also treated with another immunosuppressant. 
RESULTS: The median LVEF did not change at the last fol-
low-up (p = 0.68), but improved in 30% of patients on com-
bination therapy with prednisolone and proliferation in-
hibitors, whereas 23% of patients with prednisolone 
monotherapy experienced further worsening of LVEF. Im-
munosuppression was not used in 35% of patients. During 
follow-up, one patient underwent a successful heart trans-
plant, one had a left ventricular assist device implantation 
and one died from septic shock. 
CONCLUSION: In CS patients, ventricular arrhythmias and 
impairment of LVEF were frequently seen, but the medium-
term survival was excellent on heart failure therapy and im-
munosuppression.
FUNDING: none.
TRIAL REGISTRATION: Danish Data Protection Agency: (File 
no. RH-2016-301, I-Suite no. 04965).
Sarcoidosis is a systemic granulomatous disease with a 
poorly understood aetiology. Non-caseating granulomas 
are the main pathological findings in patients with sar-
coidosis. The role of Th1, a CD4+ T helper cell type 1 
lymphocyte that activates phagocyte-dependent inflam-
mation and the Th17 effector CD4+ T cell, which is a me-
diator of inflammation and granuloma development, is 
well documented in sarcoid formation [1, 2]. Sarcoidosis 
usually presents in the lung but may also involve lymph 
nodes, the skin, the eye, the central nervous system and 
the heart. Even though it is a systemic disease, the mani-
festations of sarcoidosis vary widely from patient to pa-
tient and especially in those with cardiac involvement 
[3]. Clinical manifestations of cardiac sarcoidosis (CS) in-
clude conduction disturbances, atrial and ventricular ar-
rhythmias and ventricular dysfunction. CS is reported to 
be found in 5% of patients with extra-cardiac sarcoidosis 
and it is clinically silent in more than 20% of cases [3, 4], 
but autopsy and imaging reports of patients with extra-
cardiac sarcoidosis have shown noncaseating granu-
lomatous myocardial infiltration   with a prevalence of 
25-80%, varying by ethnicity [5].
Reports on diagnostic findings, treatment and out-
come for CS are sparse and more knowledge is clearly 
needed [5, 6]. The main purpose of this investigation 
was to assess the clinical presentation, response to 
treatment and prognosis of patients with CS. 
METHODS  
This was a single-centre, retrospective study of patients 
diagnosed with CS from January 2006 to December 2016 
at Rigshospitalet, Copenhagen, Denmark. During the 
study period, all patients admitted to the Department of 
Cardiology (including the Department for Lung Trans-
plantation) with a diagnosis of sarcoidosis (International 
Classification of Diseases (ICD)-10 DD86), were identified 
using the hospital’s electronic filing system. The medical 
records of the patients were reviewed systematically 
and examined in order to identify patients with cardiac 
involvement. Patients were selected for review if it was 
documented that they had cardiac findings or symp-
toms, i.e. dyspnoea, syncope, palpitations, chest pain, 
fatigue or dizziness, and were included if fully or partially 
fulfilling the diagnostic criteria for CS as presented by 
the Japanese Ministry of Health and Welfare (JMHW) 
from 1993 [6] or the modifications hereof  [7]. We also 
included patients with ventricular tachycardia (VT), com-
plete heart block or abnormal electrocardiography (ECG) 
with right-bundle brunch block, left-bundle brunch 
block, first-degree atrioventricular (AV) block and posi-
tive endomyocardial biopsy (EMB) or positive advanced 
imaging studies such as cardiac MRI, characterised by re-
gional wall motion abnormalities, abnormal wall thick-
ness, myocardial oedema and inflammation using late-
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gadolinium-enhanced (LGE) images and T2-weighted 
imaging.
For patients identified with CS, the following add-
itional parameters were recorded: age at diagnosis, gen-
der, cardiac symptoms, organ involvement in extra-car-
diac sarcoidosis, echocardiographic data including left 
ventricular ejection fraction (LVEF), ECG readings, car-
diovascular drug therapy, treatment with corticosteroids 
and other immunosuppressive medications, implanta-
tion of defibrillators like implantable cardioverter-defi-
brillator (ICD), cardiac resynchronisation therapy-defi-
brillator (CRT-D) or pacemakers and ICD therapies.
Follow-up was maintained until 31 December 2016 
with an average follow-up period of 55.4 months. The 
study was approved by the Danish Data Protection 
Agency (File no. RH-2016-301, I-Suite no: 04965). 
Patients were not asked for informed consent for this 
chart review. 
Trial registration: Danish Data Protection Agency: (File 
no. RH-2016-301, I-Suite no. 04965).
RESULTS
During the ten-year period, a total of 197 subjects with 
sarcoidosis were identified. By far, the lungs were the 
most commonly affected organ (91%). Subjects with a 
history of sarcoidosis without cardiac involvement (n = 
180) were excluded from the analysis. However, we can-
not exclude that some of the 180 patients not entered 
into the current study did, indeed, have CS as they were 
not prospectively investigated for this. A total of 17 pa-
tients with cardiac involvement were identified during 
the study period and included in this study. Given the 
retrospective nature of the study, we only included pa-
tients with a diagnosis of CS (Figure 1). The median age 
at diagnosis was 46.9 years and 59% were males. The in-
itial symptoms were dyspnoea in 70% of patients, palpi-
tation in 35% of the patients and fatigue in 23% of the 
patients. Cardiac arrest was the initial presentation in 
two patients (12%), two patients (12%) complained of 
chest pain, two patients (12%) complained of dizziness 
and one (6%) presented with bradycardia. 
Half of the patients (n = 9; 53%) were diagnosed by 
positive MRI (Table 1). An EMB was done in eight (47%) 
patients, of whom five (29%) were diagnostic of sar-
coidosis (Table 2). Subjects without a diagnostic biopsy 
and no documentation of extra-cardiac involvement (n = 
2; 12%) were diagnosed clinically by fulfilling the JMHW 
criteria which included; advanced AV block, LVEF below 
50% and an abnormal electrocardiogram with ventricu-
lar tachycardia or ventricular fibrillation. The last patient 
(n = 1; 6%) was diagnosed by positive extra-cardiac bi-
opsy of one isolated organ and advanced AV block. At 
the follow-up, 16 (94%) of the patients were alive. One 
female patient aged 37 died from septic shock after 48 
months of follow-up.
During a median follow-up of four years, 65% of pa-
tients complained of dizziness, 59% of dyspnoea, 53% 
had palpitation and only 6% had chest pain. However, 
47% of the patients who were treated with prednisolone 
monotherapy or a combination therapy with other im-
munosuppressants experienced dizziness, tiredness, 
nausea, mood changes, insomnia and Cushingoid fea-
tures.
In our study, AV conduction delay was frequently 
seen (n = 8; 47%), advanced AV block being present in 
six (35%). The second-most common abnormality in four 
(23%) patients with CS was sinus rhythm with complete 
right bundle branch block. Two patients with CS present-
ed with ventricular tachycardia and the remaining two 
(12%) had a normal ECG.
Treatment is presented in Table 3. Anti-congestive 
medications were used in 13 patients (76%), anti-arryth-
mics in 15 (88%), a defibrillator (ICD) was implanted in 
11 (65%), a CRT-D was used in two (12%) and two (12%) 
had a pacemaker implant. Of the 13 (77%) patients in 
whom an ICD or CRT-D was implanted, six (46%) re-
ceived first appropriate shock therapy after a mean fol-
TABLE 1
Positive magnetic resonance imaging (MRI) of patients based on sarcoid 
localisation in the myocardium.
Localisation                                 Positive MRI, % (n = 9)
Right ventricle 29
Left ventricle 41
Septum 35
FIGURE 1
Flow chart for the study of patients with sarcoidosis.
Sarcoidosis patients  
in 1 centre  
Jan 2006-Dec 2016 
(N = 197)
Patients with non-cardiac  
involvement
(n = 180)
Positive magnetic 
resonance imaging  
(n = 9 ≈ 53%)
Diagnosis confirmed 
by endomyocardial 
biopsy 
(n = 5 ≈ 30%)
Fully complied with 
criteria JMHW 2006 
(n = 2 ≈ 12%)
Confirmed extra-
cardiac sarcoidosis 
and advanced 
AV block 
(n = 1 ≈ 6%)
Patients with cardiac 
 sarcoidosis
(n = 17)
AV = atrioventricular block; JMHW = Japanese Ministry of Health and Welfare.
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low-up of two years and four (31%) received first anti-
tachycardia pacing therapy after a mean follow-up of 1.9 
years. One patient underwent a heart transplantation 
and one required a left ventricular assist device implan-
tation. 
The median (range) LVEF at baseline was 45 (15-
60%). Overall, LVEF did not change at the last follow-up 
45 (10-60%), regardless of treatment with prednisolone. 
In six (35%) patients with no symptoms or very mild 
symptoms, neither corticosteroids nor other immuno-
suppressants were used. In one of these patients, LVEF 
decreased significantly during follow-up.
DISCUSSION
In patients with CS, ventricular arrhythmias and impair-
ment of LVEF were frequent, which is in line with pre-
vious research [8]. The clinical presentation of the pa-
tients in our study was comparable to findings in other 
studies, i.e. symptoms of serious cardiac arrhythmias, 
heart failure, sudden cardiac death or diffuse mild symp-
toms of dizziness, tiredness and palpitation [9-13]. In ad-
dition, CS is often clinically silent and may present with 
sudden cardiac death [10, 14]. ECG and echocardiog-
raphy may be normal in the initial phase of the disease 
[15]. While the heterogeneous presentation of CS makes 
the diagnosis challenging, it is essential to identify and 
treat CS at an early stage to avoid malignant arrhythmia 
and development of heart failure. 
This single-centre study shows that more than half 
of patients with CS were middle-aged men (59%). This is 
in contrast to the study by Kandolin et al [11], which re-
ported that CS was more frequently found in young or 
middle-aged women.
LGE has demonstrated an improved sensitivity for 
the diagnosing of CS. Smedema et al [12] have com-
pared the JMHW criteria with CMR sensitivity for CS and 
found that all 12 patients who fulfilled the JMHW cri t-
eria had a positive CMR. Patel et al [13] examined the 
prognostic value of LGE in CMR and demonstrated that 
patients with LGE had a nine-fold higher occurrence of 
adverse events with arrhythmias and cardiac death than 
non-LGE patients. A study by Greulich et al [16] explored 
a large population of 155 patients with systemic sarco-
idosis who were examined by CMR for possible CS. After 
a follow-up of 2.6 years, they concluded that the pres-
ence of positive LGE by CMR was the best independent 
predictor for potential future lethal events like cardiac 
death, aborted sudden cardiac death, appropriate ICD 
therapy or ventricular tachycardia.  In our study, 53% of 
patients were retrospectively diagnosed by positive 
TABLE 2
Symptoms, diagnostic features and extra-cardiac sarcoid involvement.
Patient no. EMB/MRI Initial symptoms Extra-cardiac sarcoidosis LVEF, % ECG Japanese criteria
1 ND/ND Palpitation, dyspnoea Renal 60 3rd-degree AV block +
2 Pos./pos. Dyspnoea - 40 SR + 1st-degree AV block +
3 Neg./pos. Palpitation, dyspnoea,
dizziness
- 60 SR + 1st-degree AV block +
4 ND/pos. Dyspnoea Pulmonary Cutaneous 30 VT +
5 Pos./ND Dyspnoea Pulmonary 60 SR +
6 Neg./pos. Palpitation, dyspnoea Pulmonary 35 VT +
7 Neg./pos. Cardiac arrest Pulmonary 60 SR
8 ND/ND Chest pain - 30 VT ⇒ multiple PVC + SVES with 
Q-wave ⇒ 3rd-degree AV block
+
9 Pos./ND Palpitation, dyspnoea, 
tiredness
- 30 SR + LBBB +
10 ND/pos. Dyspnoea Pulmonary 60 SR + 3rd-degree AV block +
11 ND/pos. Chest pain, dyspnoea Mediastinal lymph node 60 SR + CRBBB +
12 ND/pos. Palpitation, dyspnoea, 
tiredness
Pulmonary 45 SR + 3rd-degree AV block +
13 Pos./ND Dyspnoea, tiredness - 15 SR + CRBBB +
14 Pos./ND Chest pain, tiredness, dys-
pnoea
- 20 SR + CRBBB +
15 ND/pos. Syncope palpitation, dyspnoea Pulmonary 60 SR + 3rd-degree AV block +
16 ND/ND Cardiac arrest, dyspnoea - 30 VF ⇒ SR + 3rd-degree AV block +
17 ND/ND Bradycardia Mediastinal lymph node 60 SR + multiple PVC +
AV = atrioventricular; CRBBB = complete right bundle branch block; EMB = endomyocardial biopsy; ECG = electrocardiography; LBBB = left bundle branch block; LVEF = left ventricle 
ejection fraction; MRI = magnetic resonance imaging; ND = not done; neg. = normal answer; pos. = positive answer; PVC = premature ventricular complexes; SR = sinus rhythm; SVES = 
supraventricular extrasystoles; VF = ventricle defibrillation; VT = ventricle tachycardia.
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CMR. Three of the patients in our cohort underwent flu-
or odeoxyglucose (FDG)-PET and had positive scans. FDG-
PET technique may supplement and in some instances 
replace MRI and will likely play a greater role in the fu-
ture [17]. It is possible that a proportion of the 180 pa-
tients without a CS diagnosis did, in fact, have cardiac in-
volvement. Further studies are required to investigate 
early or “silent” CS in patients with extra-cardiac sar-
coidosis [3, 4] and possibly the new non-invasive tech-
niques will help provide this information
Immunosuppressive therapies, specifically cortico-
steroids, have been shown to be effective in the preven-
tion of further granulomatous affection of the myocar-
dium and subsequent organ dysfunction, although large 
studies are not available [7]. Some studies suggest that 
administering steroids in CS patients may prevent devel-
opment of LV dysfunction if LVEF is initially normal [15, 
18] and may even improve moderately depressed LV 
function (LVEF 35-55%). However , beneficial effects of 
steroid on severely depressed LVEF have not been re-
ported [15, 19]. In our study, 11 patients (65%) were 
treated with prednisolone, and other immunosuppres-
sants were added in five patients who had improved 
LVEF. Four patients out of eleven were treated only with 
prednisolone and had reduced LVEF at follow-up and 
two of them had no changes in LVEF regardless of pred-
nisolone treatment. In the remaining six (35%) patients 
with no symptoms or very mild symptoms, neither cor-
ticosteroids nor other immunosuppressants were used.  
In one of these patients, LVEF decreased significantly 
during follow-up. Interestingly, patients treated with 
combination therapy with prednisolone and prolifer-
ation inhibitors exhibited improved LVEF; still, overall, 
LVEF did not change with a median (range) at baseline of 
45% (15-60) or at the last follow-up (45% (10-60)) with a 
p-value of 0.68.
Given the observational nature of the study, it is 
not possible to determine if this difference in outcome 
was related to treatment. Also, caution in interpreting 
any differences between outcomes should be exerted 
given the low number of patients. As such, the results 
are merely hypothesis-generating. Clearly, randomised 
trials of different immunosuppressive CS treatment regi-
mens are needed. Given the prevalence of the disease, 
this would require collaborative efforts between dedi-
cated centres. More than half of the patients in whom 
an ICD or CRT-D was implanted experienced appropriate 
shocks. Although ICD shocks are not exact surrogates of 
haemodynamically significant VT episodes or sudden 
cardiac death, the finding supports the guidelines rec-
ommending ICD implantation at a low threshold in CS  
[7, 20]. The medium-term survival in patients with CS 
was excellent with a median follow-up of four years, an 
average period of 55.4 months with the range of 0-120 
months. However,  despite prednisolone treatment,  
VT and reduced LVEF were frequent, which is consistent 
with findings from Finland [9]. 
CONCLUSION 
The survival in this cohort of patients with CS was excel-
lent (Figure 2), but a substantial proportion of patients 
experienced ventricular arrhythmias or worsening heart 
TABLE 3
Treatment.
Treated patients, n (%)  
(N = 17)
Anti-congestive drugs/anti-arrhythmics
ACE-I/ARB 13 (76)
Beta blocker 13 (76)
Furosemide   5 (29)
Spironolactone   5 (29)
Amiodarone   1 (6)
Eplerenone   2 (12)
Ca2+ antagonist   1 (6)
Devices
PM   2 (12)
CRT-D   2 (12)
ICD 11 (65)
Heart transplant                                                 1 (6)
LVAD        1 (6)
Immunosuppression
Corticosteroid 11 (65)
Azathioprine   3 (18)
Mycophenolate   2 (12)
Everolimus   1 (6)
Infliximab   1 (6)
None   6 (35)
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-re-
ceptor blocker; CRT-D = cardiac resynchronisation therapy-defibrillator; 
ICD = implantable cardioverter-defibrillator; LVAD = left ventricular assist 
device; PM = pacemaker.
Characteristic late enhancement in the proximal septal and lateral wall of 
the left ventricle and there probably is also some late gad enhancement 
in the right ventricular free wall.
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failure. Patients treated with a combination of predniso-
lone and other immunosuppressants appeared to fare 
better, which should be explored in further studies.
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FIGURE 2
Kaplan-Meier survival curve of the 17 patients.
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